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Background: Levetiracetam-induced rage is a rare neurobehavioral adverse effect of levetiracetam that is charac-
terized by seething rage, uncontrollable anger, ﬁts of fury, depression, violence, and suicidal tendencies. It occurs
more in patients with prior mood or psychotic disturbances. No such case has been reported in Nigeria.
Method:We report two cases of levetiracetam-induced rage. The ﬁrst patient was a 29-year-old male with a 14-
year history of intractable posttraumatic epilepsy. He was initially placed on sodium valproate and phenobarbi-
tone and later had phenobarbitone replacedwith levetiracetam.Within the ﬁrst week of initiating levetiracetam,
he became aggressive, bursted into ﬁts of fury, and attacked his siblings. Levetiracetam was stopped, and the
seething rage ceased only to reappear when it was reintroduced; hence, the complete withdrawal of levetirace-
tam. Naranjo probability score for adverse drug reaction was 8.
Results: The second patient was a 23-year-old lady who developed seething rage and made several attempts to
kill herself with a knife following addition of levetiracetam to the clonazepam and carbamazepine that she
was taking for treatment-resistant epilepsy. Withdrawal and reintroduction of levetiracetam by the relatives
led to cessation and reemergence, respectively, of the rage and suicidal tendencies. Naranjo score was 8. Leveti-
racetam was discontinued.
Conclusion: Neuropsychiatric evaluation for prior mood or psychiatric disorders in those initiating levetiracetam
therapy is suggested alongside monitoring for early features of levetiracetam-induced rage by both caregivers
and physicians. Thiswill help stem themorbidity and potentialmortality associatedwith this life-threatening ad-
verse drug reaction.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epilepsy is a chronic neurologic condition characterized by recurrent
seizures [1]. It is estimated that about 70 million people worldwide are
affected with epilepsy [2]. Approximately 70–80% of patients with epi-
lepsy (PWE) achieve seizure control with one or more antiepileptic
drugs (AEDs) [3]. Unfortunately, 20–30% of PWE will continue to have
seizures despite active treatment and are considered candidates for ep-
ilepsy surgery [4]. Paucity of facilities for epilepsy surgery has made
polytherapy using different AED combinations the only option for this
group of patients in most parts of sub-Saharan Africa. Newer AEDs
such as levetiracetam have become increasingly available in Nigeria
and have helped in achieving seizure control in some of these drug-
resistant epilepsies. Unfortunately, the association of levetiracetam
and an untoward rare neurobehavioral adverse effect is increasingly
being reported globally. It is characterized by seething rage,ent of Medicine, University of
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. This is an open access article underuncontrollable anger, ﬁts of fury, depression, violence, and suicidal ten-
dencies. Levetiracetam-induced rage and suicidality occur more in pa-
tients with prior psychiatric disturbance [5,6]; we report two cases of
levetiracetam-induced rage in which one of the cases had several sui-
cide attempts.
2. Case presentation
The ﬁrst patient was a 29-year-old male who fell from a two-storey
building at 2months of age and subsequently developed intractable sei-
zures and left hemiparesis. His body mass index was 28.4 kg/m2
(weight: 86 kg, height: 1.74 m). Initially, he took sodium valproate
(600 mg BD) and phenobarbitone (60 mg tds). His phenobarbitone
was replaced with levetiracetam at a starting dose of 250 mg twice
daily for one week and then escalated to 500 mg twice daily for the
next four weeks.
Within the ﬁrst week of taking levetiracetam, he became aggressive,
bursted into ﬁts of fury, and attacked his siblings. Levetiracetam was
stopped, and the seething rage ceased only to reappear when it was
reintroduced; hence, the complete withdrawal of levetiracetam.
Naranjo score or adverse drug reaction probability was 8 (i.e., +1 forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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+2 for appearance of the adverse event following initiation of the
suspected drug, +1 for improvement of the adverse event following
discontinuation of the suspected drug, +2 for reemergence of the reac-
tion following readministration of the drug, and +2 for the absence of
an alternative explanation for the adverse event).
The second patient was a 23-year-old lady who developed seething
rage and made several attempts to kill herself with a knife after two
weeks of initiating adjunctive levetiracetam at a starting dose of
250 mg twice daily for the ﬁrst week and then 500 mg twice daily sub-
sequently. She had been on clonazepam and carbamazepine for
treatment-resistant epilepsy. Her body mass index was 20.31 kg/m2
(weight: 52 kg, height: 1.60m).Withdrawal and reintroduction of leve-
tiracetam by the relatives led to cessation and reemergence, respective-
ly, of the rage and suicidal tendencies. Naranjo scorewas 8 as in the ﬁrst
patient. Levetiracetam was discontinued, and the levetiracetam-in-
duced rage ceased.
3. Discussion
An adverse drug reaction (ADR) describes any noxious and unin-
tended response to a drug that occurs at doses normally used in man
for prophylaxis, diagnosis, therapy, or modiﬁcation of a physiological
function [7]. Clinically signiﬁcant ADRs following emergent AEDs can
cause serious morbidity and mortality if unrecognized [8]. Levetirace-
tam is one of the emergent antiepileptic drugs that has become avail-
able to patients with epilepsy in sub-Saharan Africa, especially Nigeria.
Levetiracetam-induced rage is a rare neuropsychiatric ADR character-
ized by seething rage, uncontrollable anger, ﬁts of fury, depression, vio-
lence, and suicidal tendencies. Levetiracetam-induced rage occurs more
in patients with prior mood or psychiatric disturbance [5,6].
Ourmultiple caseswere patientswhowere beingmanaged for drug-
resistant epilepsy using multiple medications. Levetiracetam was used
to replace phenobarbitone in the ﬁrst patient who was also taking car-
bamazepine; levetiracetam was added to carbamazepine and clonaze-
pam in the second patient. In both of these patients, there was
reduction in seizure frequency despite the seething rage, ﬁts of fury,
aggressiveness, and suicidal tendencies (the second patient). In addi-
tion, the ﬁrst patient had no prior mood or psychiatric disturbance
though he was overweight and had a history of traumatic brain injury;
the second patient was initially managed for depression and had a
normal weight. In both of these patients, the neuropsychiatric features
started in the ﬁrst week of commencing levetiracetam and became
well established by the second week of therapy. The ﬁrst patient had
the neuropsychiatric adverse effect while on 250 mg twice daily of
levetiracetam; the second patient was commenced on 250 mg of
levetiracetam twice daily for the ﬁrst week and subsequently escalated
to 500 mg twice daily.
Causality assessment describes the evaluation of the likelihood that
a particular treatment is responsible for an observed adverse event
[9]. The objective causal assessments are predicated on four basic
principles—temporal eligibility, dechallenge and outcome, rechallenge
and outcome, and confounding factors [10]. The Naranjo algorithm as-
sesses the probability that an adverse event is related to a particular
drug therapy based on a list of weighted questions, which examine fac-
tors such as the temporal association of drug administration and event
occurrence, alternative causes for the event, drug levels, and previous
patient experience with the medication [11]. Both of these patients
had a Naranjo score of 8 meaning that it is probable that the neuropsy-
chiatricmanifestations seen in these patients are secondary to levetirac-
etam intake.
In a cohort of 71 Korean subjects with drug-resistant epilepsy (DRE)
receiving adjunctive levetiracetam, 3 of them (4.2%) had suicidal ten-
dencies which led to the discontinuation of the drug [6]. The investiga-
tors had argued that forced normalization, a phenomenon whereby
depressive or psychotic episodes develop in patients who becomeseizure-free after having suffered from DRE would not explain their
ﬁnding as only 1 of their patients who developed suicidal tendency
had seizure control [12]. In another study, 4 out of 517 Caucasian pa-
tients (0.7%) taking levetiracetam reported suicidal ideation [13].
It is worthy of note that while previous literature associates leveti-
racetam-induced rage and suicidal tendencies in patientswith prior his-
tory of mood or psychiatric disorder [5,6,13,14], newer studies and case
reports have described de novo presentation of levetiracetam-associat-
ed rage and suicidality in the absence of prior history ofmood or psychi-
atric disorder [15,16]. The ﬁrst patient presented here did not have any
prior psychiatric disorder and, thus, supports de novo presentation of
levetiracetam-associated rage.
Our second patient demonstrated an apparent dose-dependent rage,
aggressiveness, and suicidal tendencies similar to what has been previ-
ously documented [15]. The ﬁrst patient, on the other hand, had the as-
sociated rage and aggressiveness in a dose-independent manner which
would suggest that patient-related factors may be related to the devel-
opment of this adverse effect.
Our patients' seizures, though reduced in frequency, were not yet
controlled with the adjunctive levetiracetam. This implies that forced
normalization would also not explain their neuropsychiatric ADR.
From the foregoing, levetiracetam-associated rage, aggressiveness,
and suicidal tendencies appear to occur rarely in PWE. Both sexes may
be affected, the adverse effect could be dose-dependent or dose-
independent, and it may occur de novo or on a background of prior psy-
chiatric disorder and is not readily explainable by the theory of forced
normalization.
The strength of these ﬁndings though germane and worthy of con-
sideration pales in signiﬁcance considering the fact that they are predi-
cated on results from only two PWE taking levetiracetam. Nevertheless,
a well designed prospective study to determine the prevalence and pre-
dictors of levetiracetam-induced rage and suicidality in a large cohort of
Nigerian PWE taking levetiracetam is suggested.
4. Conclusion
Neuropsychiatric evaluation for prior mood or psychiatric disorders
in those initiating levetiracetam treatment is suggested alongside con-
tinual monitoring for early features of levetiracetam-induced rage and
suicidality by both caregivers and physicians. Thiswill help in stemming
the adverse morbidity and potential mortality associated with this ad-
verse effect.
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